Broad Spectrum Antiviral Remdesivir for the Treatment of Emerging Viral Infections with High Outbreak Potential
Agenda (February 27, 2020, Thursday)
(This event will be broadcast to you through Zoom Conference; agenda is based on US Pacific Time)
12:00 pm - 12:10 pm Introduction to CABS, Yang Tian, President of CABS
12:10 pm - 12:40 pm Discovery and Preclinical Data of Remdesivir, Danielle Porter, PhD, Director of Virology, Gilead Sciences
12:40 pm - 1: 10 pm Development of Remdesivir, Tomas Cihlar, Vice President of Virology, Gilead Sciences
1:10 pm - 1:30 pm Q&A
Webinar Zoom Access Link:
Join from a PC, Mac, iPAD or Mobile Phone via this link
Meeting URL: https://zoom.com.cn/j/540026848
Mobile one tap: US +16465588656,,540026848# or +16699009128,,540026848#
Join by Phone:
US +1 646 558 8656 or +1 669 900 9128
Meeting ID: 540 026 848
International Numbers: https://zoom.com.cn/u/auAXTwiBl
Due to large number of registrants, please join the webinar 5 minutes before the starting time (12pm US Pacific Time).
Any question? Please email firstname.lastname@example.org
Danielle Porter, PhD, is a Director of Virology at Gilead Sciences. She obtained her undergraduate degree in biology at Dartmouth College and earned a PhD in virology from Harvard University. After spending several years at Novartis and then Lawrence Livermore National Laboratory, she joined Gilead in 2010. During her time at Gilead, she has worked on clinical trials for novel HIV and RSV therapeutics as well as emerging viral diseases. Most recently, she has been leading the nonclinical program for Remdesivir, which was recently studied in a clinical trial of acute Ebola disease in the Democratic Republic of the Congo and is now under investigation for efficacy against 2019-nCoV.
Tomas Cihlar, PhD, is a Vice President of Virology at Gilead Sciences with responsibility for coordinating preclinical antiviral research including projects on treatment, prevention, and cure of HIV, HBV, respiratory viruses, and emerging viruses. Dr. Cihlar joined Gilead after receiving his PhD in Biochemistry from the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague, Czechia. Over the years, he has contributed to the development and regulatory approval of multiple Gilead’s antiviral products including all Gilead HIV drugs and their combinations. Together with his colleagues, he established research programs focused on long-acting antiretrovirals, in addition to a portfolio of projects aiming at the cure of HIV and HBV, and multiple programs for the treatment of respiratory and emerging/neglected viruses. Dr. Cihlar has served as a project lead for Gilead’s program on remdesivir, a broad-spectrum antiviral agent in clinical testing against Ebola infection and more recently against the 2019 new coronavirus. In past, Dr. Cihlar served on the Board of Directors of the International Society of Antiviral Research.
Remdesivir (GS-5734) is a nucleotide prodrug with potent in vitro activity against multiple emerging virus families with high outbreak potential including filoviruses, coronaviruses and paramyxoviruses. The mechanism of remdesivir’s antiviral activity is through delayed chain termination of viral RNA transcription following the incorporation of the active intracellular nucleoside triphosphate metabolite into RNA as shown in biochemical assays using recombinant Ebola, Nipah, and respiratory syncytial virus (RSV) RNA dependent RNA polymerases. Remdesivir has demonstrated in vivo efficacy against Ebola virus in non-human primates which has led to its inclusion in clinical studies evaluating the effects of remdesivir treatment in acute Ebola virus disease (EVD) as well as in male EVD survivors with prolonged viral shedding in semen. The efficacy of remdesivir against other emerging viral infections has been demonstrated in animal models for Marburg virus, Nipah virus, sudden acute respiratory syndrome (SARS) coronavirus, and Middle East respiratory syndrome (MERS) coronavirus. Together, the current preclinical and clinical profiles of remdesivir support its further development as a broad spectrum antiviral to manage emerging viral infections with high mortality and significant outbreak potential including the novel coronavirus, 2019-nCoV.
Special Thanks to Zoom Video Communications and 北京幸福公益基金会 for technical support.
Free online registration – $0 (USD) - 251 left
Zoom Conference Webinar meeting ID, direct link and dial in information will be sent to your registration email 3 days before the event.